Clinical trials: Treatment Resistant Major Depressive Disorder
Major Depressive Disorder
Study to Assess the Effects of Intranasal Ketamine Along With rTMS for Patients With Treatment-resistant Major Depressive Disorder (TRD)
An open label study to assess the safety, tolerability, and effects of intranasal Ketamine in combination with rTMS for patients with treatment-resistant major depressive disorder (TRD).
- Trial name
- NCT04352621
- Testing
- intranasal ketamine, rTMS treatment
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
Treatment Resistant Major Depression Disorder
DBS of the Habenula for Treatment- Resistant Major Depression
The habenula(Hb) is an epithalamic structure located at the center of the dorsal diencephalic conduction system, a pathway involved in linking forebrain to midbrain regions.
- Trial name
- NCT03347487
- Testing
- Deep brain stimuation system implantation
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Ruijin Hospital
Major Depressive Disorder
An Open Label Study of the Genecept™ Assay in Treatment Resistant Depression
The purpose of this study is to examine the potential impact of the assay in terms of depression severity as measured by change in Clinical Global Impressions (CGI) scale at 3 months.
- Trial name
- NCT01438242
- Testing
- Genecept Assay
- Where
- United States
- Sponsor
- Genomind, LLC
Depression
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression
This study aims to examine the antidepressant efficacy of riluzole, employing a randomized, double-blind, placebo-controlled, adjunctive trial in treatment-resistant major depressive disorder (TRD).
- Trial name
- NCT01204918
- Testing
- Riluzole
- Where
- 3 sites in United States
- Volunteers
- 104 people
- Sponsor
- Yale University
Major Depressive Disorder, Treatment Resistant Depression
MAO-B Occupancy in Depressed Patients
The study is looking at assessing monoamine oxidase B (MAO-B) occupancy in depressed patients before and after medication treatment using positron emission tomography (PET) scan.
- Trial name
- MOCP (NCT04841798)
- Testing
- [11C]SL25.1188 PET radiotracer
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depression
Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression
The investigators plan to use optical brain imaging technology to observe patients with current major depression before, during, and after repetitive Transcranial Magnetic Stimulation (rTMS) clinical treatment.
- Trial name
- NCT01768052
- Testing
- functional Near Infrared Spectroscopy
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mclean Hospital
Major Depressive Disorder, Suicide
i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
Approximately four thousand Canadians die by suicide every year, and suicide is the second leading cause of death in youth and young adults (15-34 years).
- Conditions
- Major Depressive Disorder, Suicide, Treatment Resistant Depression
- Trial name
- Ket-CBT (NCT06480500)
- Testing
- Ketamine hydrochloride, i-CBT (Internet-based Cognitive Behavioural Therapy), Midazolam Hydrochloride
- Where
- Canada
- Volunteers
- 76 people
- Sponsor
- University Health Network, Toronto
Major Depressive Disorder
Maintenance rTMS for Treatment-resistant Depression (TRD): a One-year Double Blind Controlled Study
number of center : 1 duration of study : 24 months recruitement time : 23 months Aim :Principal Evaluate the interest of maintenance rTMS in a one-year double blind randomized controlled study for TRD patients.
- Trial name
- TMS/DEP (NCT02383693)
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Centre hospitalier de Ville-Evrard, France
Treatment Resistant Depression
COpenhagen Magnetic Personalized Accelerated Brain Circuit Therapy for Treatment Resistant Depression
The CoMPACT trial is a randomized double-blinded sham-controlled study aimed at testing a novel accelerated and personalized transcranial Magnetic Stimulation (TMS) treatment for patients with Treatment Resistant Depression…
- Trial name
- CoMPACT (NCT06895863)
- Testing
- MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil., Device: MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil.
- Where
- 3 sites in Denmark
- Volunteers
- 78 people
- Sponsor
- Danish Research Centre for Magnetic Resonance
Treatment-Resistant Major Depressive Disorder
Avatar Therapy in Virtual Reality for Treatment-Resistant Major Depressive Disorder: A Pilot Study
This pilot clinical trial aimed to evaluate the short-term efficacy of Avatar therapy for treatment-resistant major depressive disorder
- Trial name
- NCT07112261
- Testing
- Avatar Therapy
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Major Depressive Disorder (MDD), Treatment-resistant Depression (TRD)
Comparison of Efficacy of Minocyclin and Celecoxib as Adjunctive Treatment in Treatment Resistant Cases of Major Depressive Disorder
This randomized controlled study was conducted to compare the effectiveness of minocycline and celecoxib as add-on treatments in patients with treatment-resistant major depressive disorder.
- Trial name
- NCT07804979
- Testing
- Minocycline, Celecoxib
- Where
- Pakistan
- Volunteers
- 78 people
- Sponsor
- Lahore General Hospital
Depression
Pulsed Electro Magnetic Fields (PEMF) Treatment in Patients With Treatment-Resistant Major Depression in Ongoing Pharmacological Treatment of Depression
About 30% of patients with major depression are treatment resistant to pharmacological treatment. In the search for new methods to treat depression a great interest has been put into the use of electromagnetic fields.
- Trial name
- NCT00287703
- Testing
- Pulsating Electro-Magnetic Fields
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Hillerod Hospital, Denmark
Treatment Resistant Depression, Major Depressive Disorder
Sustained Mood Improvement With Laughing Gas Exposure: A Randomized Controlled Pilot Trial
The purpose of the study is to investigate a short-term treatment option for major depressive disorders by administering nitrous oxide gas.
- Trial name
- SMILE (NCT04957368)
- Testing
- Nitrous Oxide 99 %, Oxygen + Midazolam
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Unity Health Toronto
Resistant Depression, Treatment
TReAtment With CombinedExercise in Patients With Resistant Major Depression
Major depressive disorder is one of the most prevalent and disabling mental disorders worldwide. Forty percent of people with major depressive disorder are in moderate remission, with the remainder meeting the criteria for…
- Trial name
- TRACE-RMD (NCT05136027)
- Testing
- Combined training
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- University of the Basque Country (UPV/EHU)
Depression
AZD6765 for Treatment Resistant Depression
The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.
- Trial name
- NCT00491686
- Testing
- AZD6765
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Treatment Resistant Depression, Major Depressive Disorder
Simvastatin as an Augmentation Treatment for Treatment Resistant Depression: Randomized Controlled Trial.
In this double blind, randomized placebo controlled trial we aim to determine the efficacy of simvastatin as an add-on treatment for treatment resistant depression.
- Trial name
- DepSTAT (NCT03435744)
- Testing
- Simvastatin 20 mg
- Where
- 4 sites in Pakistan
- Volunteers
- 150 people
- Sponsor
- Pakistan Institute of Living and Learning
Subjects Had Unipolar, Non-psychotic Major Depression
Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression
Atypical neuroleptics may have antidepressant qualities in bipolar depression and in unipolar depression. Some data support the use of both Risperidone and Olanzapine, but there are no direct comparisons of their relative…
- Trial name
- NCT01282632
- Testing
- Risperidone, Olanzapine
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- Sunnybrook Health Sciences Centre
Magnetic Resonance Imaging, Major Depression
Ketamine Alcohol (in Treatment-Resistant Depression)
A single subanesthetic dose infusion of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has rapid and robust antidepressant effects in patients with treatment-refractory major depressive disorder (TRD).
- Conditions
- Magnetic Resonance Imaging, Major Depression, Alcoholism
- Trial name
- NCT02122562
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mark Niciu
Depressive Disorder, Bipolar Disorder
Multimodal Biomarkers of Electroconvulsive Therapy in Severe and Treatment-resistant Depression
Electroconvulsive therapy (ECT) is a widespread and safe stimulation method that has been used successfully for decades in psychiatric diseases such as severe or therapy-resistant depression.
- Trial name
- DetECT (NCT05463562)
- Where
- Germany
- Volunteers
- 134 people
- Sponsor
- Max-Planck-Institute of Psychiatry
Major Depressive Disorder, Treatment Resistant Depression
40 Hz Light Neurostimulation for Patients With Depression (FELIX)
Recent research in mice models of Alzheimer's disease (AD) has demonstrated that one hour per day of exposure to 40 Hz flickering light therapy can halt the disease's progression, and improve cognition and memory.
- Trial name
- NCT05680220
- Testing
- Neurostimulation System (NSS): Active Setting
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Klaus Martiny